Highlights
1 patentProfile claimed by owner
About
Filling the Cardiac Gap
Coramaze Technologies develops the Tripair, a simple, rapid, and effective percutaneous treatment for tricuspid valve disease. The treatment is intended to improve quality of life and reduce morbidity for heart failure patients suffering from tricuspid regurgitation. The Tripair implant is anchored a-traumatically in the right atrium, enabling full retrievability and intraprocedural efficacy evaluation while reducing regurgitation even in the most severe cases.
Identity
| Name | Coramaze Technologies |
|---|---|
| Slug | coramaze |
| Type / kind | startup |
| Crunchbase ID | coramaze-technologies |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAkKj_6LEIDA |
Status
| Status | active |
|---|---|
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ region/district | Center District |
| HQ city | Petah Tikva |
| HQ address | Totseret ha-Arets St 3, Petah Tikva, Israel |
Web & social
| Website | https://tripairtechnology.com |
|---|
Classifications
Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesMedical DevicesMedical Treatment & Therapeutics
Technologies
Materials & SubstancesImplants
Target customers
Healthcare & Life SciencesHealthcareProviders
Business models
B2B
Tags
heart-failurevascularcardiologycathetersminimally-invasiveheart-diseasesmedical-technologiescardiovascularmedical-devices
Funding
| Total raised | $6.3M |
|---|---|
| Current stage | Series A |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}